- Only 13.8% of all biopharma drug lines on average are ever approved – wasting a whopping 86.2% of total R&D investment.
- The traditional drug pricing model is under a bipartisan political and economic attack that will last far beyond 2020.
- Biopharma companies like yours have recovered $750,000+ in operating costs to fund R&D and other priorities through active asset management and valuation strategies.
Find New Funds for
Research and Development
or any of your company’s current priorities through asset management and valuation.
New market research analysis reveals:
I am raw html block.
Click edit button to change this html
Sponsored by the Tiger Liquidity Services Biopharma Partnership